1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow Nelson Hamerschlak: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory | Phase 1 | Recruiting | Nelson Hamerschlak | 30 | 2023-02-07 | 2025-09-25 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Cyclophosphamide (1) · fludarabine (1)
Brazil (1)